EpilepsyNCT07190976
The Value of EEG in Stroke Units
An observational study of Epilepsy, run by Attikon Hospital at 1 site in Greece.
Trial summary
Τhe aim of the study is to investigate the role of EEG both in predicting epileptogenesis in patients with acute stroke and in detecting and clarifying the clinical significance of subclinical epileptic seizures in a stroke unit. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Epilepsy
- What is being tested?
- Routine EEG
- How many people
- 100 participants
- Where
- 1 siteGreece
- Study dates
- 1 Mar 2024to 30 Sep 2026
- How long will I take part?
- 2 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Patients with acute ischemic or hemorrhagic stroke in whom it is not possible to perform an electroencephalogram within the first 7 days after the event, as well as patients who themselves or their legal representatives do not consent to participation, will be excluded from the study.
Who may be able to join
None listed.
Who cannot join
- -
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Greece1 site, 1 recruiting
- Recruiting
University General Hospital "ATTIKON"- General Hospital of West Attica "H AGIA VARVARA" 2nd Neurology Clinic, NKUA
Chaïdári, Athens, 12462
Panagiota Eleni Tsalouchidou, MD PhD, +30 6984158124, pania.tsalouchidou@gmail.com
Zafeirenia Vlakou, MD MSc, +30 6940200961, zvlakou@gmail.com
About this study
Τhe aim of the study is to investigate the role of EEG both in predicting epileptogenesis in patients with acute stroke and in detecting and clarifying the clinical significance of subclinical epileptic seizures in a stroke unit. More specifically, the performance of routine EEG in patients with ischemic or hemorrhagic stroke who are hospitalized in the Stroke Unit within the first days after the event, regardless of the presence of clinical indications, and the identification of risk factors for the early development of epilepsy in the course of these patients' disease constitute the central research question. The identification of patients with subclinical electroencephalographic seizures and the impact of such events on functional outcome, as well as their association with the development of epilepsy, are set as secondary research objectives.
- Conditions
- Epilepsy
- Being tested
- Routine EEG
- Medical subject headings
- Epilepsy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Routine EEGOther
The study is observational. No intervention is anticipated. Patients will be submitted to EEG recording within the first seven days of stroke
Routine EEGOther
The study is observational
| Study group | Role | What they receive |
|---|---|---|
| Adult patients with acute ischemic or hemorrhagic stroke | Not described Receives: Other: Routine EEG |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of post-stroke epilepsy
Measured: 4 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Sep 2025
- Study start1 Mar 2024
- Primary completion30 Sep 2026 (estimated)
- Study completion30 Sep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for EpilepsyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
- Target duration
- 2 Years
Sponsor and investigators
- Lead sponsor
- Attikon Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Panagiota Eleni Tsalouchidou, Attikon Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07190976
- Sponsor's protocol ID
- 48827/27.05.2024
- Status last verified
- Sep 2025
- First submitted
- 17 Sep 2025
- Last updated
- 24 Sep 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Value of EEG in Stroke Units
- ClinicalTrials.gov ID
- NCT07190976
- Acronym / sponsor ID
- 48827/27.05.2024
- Conditions
- Epilepsy
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Attikon HospitalUniversity, hospital or other
- Study start
- 1 Mar 2024 (actual)
- Primary completion
- 30 Sep 2026 (estimated)
- Study completion
- 30 Sep 2026 (estimated)
- First posted
- 24 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Τhe aim of the study is to investigate the role of EEG both in predicting epileptogenesis in patients with acute stroke and in detecting and clarifying the clinical significance of subclinical epileptic seizures in a stroke unit. More specifically, the performance of routine EEG in patients with ischemic or hemorrhagic stroke who are hospitalized in the Stroke Unit within the first days after the event, regardless of the presence of clinical indications, and the identification of risk factors for the early development of epilepsy in the course of these patients' disease constitute the central research question. The identification of patients with subclinical electroencephalographic seizures and the impact of such events on functional outcome, as well as their association with the development of epilepsy, are set as secondary research objectives.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 2 Years
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Adult patients with acute ischemic or hemorrhagic stroke | – | Other: Routine EEG |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with acute ischemic or hemorrhagic stroke in whom it is not possible to perform an electroencephalogram within the first 7 days after the event, as well as patients who themselves or their legal representatives do not consent to participation, will be excluded from the study.
Key inclusion criteria (0 listed)
Key exclusion criteria (1 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Routine EEGThe study is observational. No intervention is anticipated. Patients will be submitted to EEG recording within the first seven days of stroke | Other | Adult patients with acute ischemic or hemorrhagic stroke |
| Routine EEGThe study is observational | Other | Adult patients with acute ischemic or hemorrhagic stroke |
Primary outcome
Incidence of post-stroke epilepsy
Time frame: 4 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Sep 2025.
Related trials for Epilepsy
Enrolling by invitation
Neural Mechanisms for Stopping Ongoing Speech Production (Study 2)
Epilepsy, Speech
Recruiting
Identification of Biomarkers for Vagus Nerve Stimulation in Patients With Refractory Epilepsy
Refractory Epilepsy
RecruitingObservational study
Tumor Related Epilepsy
Epilepsy, Cancer
RecruitingObservational study
Evaluation and Treatment of Neurosurgical Disorders
Neurologic Disorders
Active, not recruitingPhase 2
A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy
Focal Epilepsy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
University General Hospital "ATTIKON"- General Hospital of West Attica "H AGIA VARVARA" 2nd Neurology Clinic, NKUA
Chaïdári, Greece
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Epilepsy, run by Attikon Hospital at 1 site in Greece.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 0 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 24 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Greece. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of post-stroke epilepsy (time frame: 4 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Sep 2025.